TSE:ONC

Oncolytics Biotech Stock Forecast, Price & News

C$3.72
+0.02 (+0.54 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
C$3.51
Now: C$3.72
C$3.77
50-Day Range
C$3.37
MA: C$4.25
C$5.80
52-Week Range
C$1.81
Now: C$3.72
C$6.06
Volume165,432 shs
Average Volume308,316 shs
Market CapitalizationC$196.30 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has collaboration agreements with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-403-6707380
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash FlowC$0.58 per share
Book ValueC$0.54 per share

Profitability

Miscellaneous

Market CapC$196.30 million
Next Earnings Date5/14/2021 (Estimated)
OptionableNot Optionable

Headlines

Oncolytics Biotech (ONCY) Enters Overbought Territory
March 25, 2021 |  finance.yahoo.com
Is Oncolytics Biotech, Inc. (ONCY) A Good Stock To Buy?
November 26, 2020 |  finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

1.25 out of 5 stars

Analyst Opinion: 3.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
C$3.72
+0.02 (+0.54 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ONC News and Ratings via Email

Sign-up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Oncolytics Biotech (TSE:ONC) Frequently Asked Questions

Is Oncolytics Biotech a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Oncolytics Biotech stock.
View analyst ratings for Oncolytics Biotech
or view top-rated stocks.

What stocks does MarketBeat like better than Oncolytics Biotech?

Wall Street analysts have given Oncolytics Biotech a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Oncolytics Biotech wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Oncolytics Biotech's next earnings date?

Oncolytics Biotech is scheduled to release its next quarterly earnings announcement on Friday, May 14th 2021.
View our earnings forecast for Oncolytics Biotech
.

How were Oncolytics Biotech's earnings last quarter?

Oncolytics Biotech Inc. (TSE:ONC) released its quarterly earnings data on Friday, March, 5th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by $0.05.
View Oncolytics Biotech's earnings history
.

How has Oncolytics Biotech's stock been impacted by Coronavirus?

Oncolytics Biotech's stock was trading at C$2.37 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ONC stock has increased by 57.0% and is now trading at C$3.72.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ONC?

3 brokers have issued 12-month price objectives for Oncolytics Biotech's stock. Their forecasts range from C$6.00 to C$6.00. On average, they anticipate Oncolytics Biotech's stock price to reach C$6.00 in the next year. This suggests a possible upside of 61.3% from the stock's current price.
View analysts' price targets for Oncolytics Biotech
or view top-rated stocks among Wall Street analysts.

Who are Oncolytics Biotech's key executives?

Oncolytics Biotech's management team includes the following people:
  • Dr. Matthew C. Coffey, Pres, CEO & Director
  • Mr. Kirk J. Look C.A., CA, Chief Financial Officer
  • Mr. Andrew R. de Guttadauro, Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc (Age 54, Pay $544.58k)
  • Mr. John Mark Lievonen B.B.A., F.C.A., M.B.A., CM, FCPA, FCA, LLD, Consultant
  • Dr. Thomas C. Heineman M.D., Ph.D., Global Head of Clinical Devel. & Operations
  • Jon Patton, Director of Investor Relations & Communication
  • Dr. Grey Wilkinson Ph.D., Scientist of Translational Medicine
  • Dr. Daniel Douglas Von Hoff FACP, M.D., F.A.C.P., Consultant (Age 73)

Who are some of Oncolytics Biotech's key competitors?

What other stocks do shareholders of Oncolytics Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncolytics Biotech investors own include Oncolytics Biotech (ONCY), (ONCYF) (ONCYF), Resverlogix (RVX), Ballard Power Systems (BLDP), (ECA), ProMetic Life Sciences (PLI), Bombardier (BDRBF), Birchcliff Energy (BIR), Enbridge (ENB) and First Majestic Silver (FR).

What is Oncolytics Biotech's stock symbol?

Oncolytics Biotech trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ONC."

How do I buy shares of Oncolytics Biotech?

Shares of ONC and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Oncolytics Biotech's stock price today?

One share of ONC stock can currently be purchased for approximately C$3.72.

How much money does Oncolytics Biotech make?

Oncolytics Biotech has a market capitalization of C$196.30 million.

What is Oncolytics Biotech's official website?

The official website for Oncolytics Biotech is www.oncolyticsbiotech.com.

Where are Oncolytics Biotech's headquarters?

Oncolytics Biotech is headquartered at 1167 Kensington Cres Nw Suite 210 Calgary Alberta Canada T2n 1X7, CALGARY, AB 00000, Canada.

How can I contact Oncolytics Biotech?

Oncolytics Biotech's mailing address is 1167 Kensington Cres Nw Suite 210 Calgary Alberta Canada T2n 1X7, CALGARY, AB 00000, Canada. The company can be reached via phone at +1-403-6707380.


This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.